News Release

Active surveillance for low-risk prostate cancer: New data on risk factors for switching to active treatment

Tumor-related factors affect time to conversion – but race does not

Peer-Reviewed Publication

Wolters Kluwer Health

Journal of Urology Infograhic

image: Journal of Urology Infographic view more 

Credit: Journal of Urology

September 10, 2021 – For men with "low-risk" prostate cancer initially managed with active surveillance, cancer-related factors such as tumor grade and size are key risk factors for conversion to active treatment, reports a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Black men on active surveillance may not have shorter times to definitive treatment as previously reported from studies using Veterans Health Administration data. "Our study is the largest to assess the time to conversion from active surveillance to treatment for prostate cancer and provides new data on factors affecting the outcomes of this increasingly used management strategy," comments William J. Catalona, MD, of Northwestern University Feinberg School of Medicine, Chicago.

Findings may help predict outcomes of active surveillance

Active surveillance is used to monitor slow-growing, low-risk or localized prostate cancer rather than treating it straight away. It typically involves regular prostate-specific antigen (PSA) screenings, prostate exams, imaging studies, and repeat biopsies to carefully monitor prostate cancer misclassification, growth, or progression without compromising long-term outcomes. The aim of active surveillance is to avoid or delay unnecessary treatment and its side effects.

Active surveillance is increasingly viewed as the preferred approach for management of lower-risk prostate cancer. However, there is limited information on how long patients remain on active surveillance before converting to active or definitive treatment, such as surgery or radiation therapy.

Dr. Catalona and colleagues analyzed data on 6,775 patients with prostate cancer managed with active surveillance at 28 medical centers in a National Cancer Institute-sponsored Prostate SPORE (Specialized Program of Research Excellence) project (P50CA180995) study. Sixty-eight percent of the men were classified as having low-risk disease, based on factors including the Gleason grade, which assess the aggressiveness of cancer cell behavior; tumor stage, which reflects how far the cancer has spread; and the number of positive biopsy specimens (cores).

At a median follow-up time of 6.7 years, one-third of men had converted to active treatment. After adjustment for other factors, six cancer-related or clinical factors were independently related to shorter conversion times: higher Gleason grade, higher PSA level, higher tumor stage, and higher number of positive biopsy cores, more recent year of diagnosis, and younger age, confirming and expanding previous reports.

A preliminary analysis suggested that patients with high-volume, low Gleason grade tumors behaved more like high-risk patients than like low- or intermediate-risk patients, and the time to conversion was unrelated to the patients' self-reported race/ethnicity or to DNA markers of genetic ancestry. That's in contrast to some previous studies suggesting that Black men have more biologically aggressive prostate cancer and "may be managed with active surveillance less frequently in clinical practice," according to the authors. These preliminary findings and the association with the more recent year of diagnosis – reflecting recent, more liberal criteria for surveillance – are novel and require confirmation in other studies.

"Our study suggests that how long patients remain on active surveillance is affected mainly by higher-risk tumor factors," Dr. Catalona adds. "The findings will be helpful to physicians and patients as they discuss and make decisions about treatment options for low-risk prostate cancer."

Click here to read “Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort”

DOI: 10.1097/JU.0000000000001937


About The Journal of Urology®

The Official Journal of the American Urological Association (AUA), and the most widely read and highly cited journal in the field, The Journal of Urology® brings solid coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of urology. This premier journal presents investigative studies on critical areas of research and practice, survey articles providing brief editorial comments on the best and most important urology literature worldwide and practice-oriented reports on significant clinical observations. The Journal of Urology® covers the wide scope of urology, including pediatric urology, urologic cancers, renal transplantation, male infertility, urinary tract stones, female urology and neurourology.

About the American Urological Association

Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has nearly 24,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health care policy. To learn more about the AUA visit:

About Wolters Kluwer

Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.

Wolters Kluwer reported 2020 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,200 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit and follow us on LinkedIn and Twitter @WKHealth.

For more information, visit, follow us on TwitterFacebookLinkedIn, and YouTube.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.